Evidence map›Paper›PMID 23092358›Full record

ArticleBMC public health2012

Ability of a biomarker-based score to predict death from circulatory disease and cancer in NHANES III.

Mieke Van Hemelrijck, Monika Eichholzer, David Faeh, Sabine Rohrmann

Abstract read
In one paragraph

Article in BMC public health, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Allostatic Load and Healthcare Access Among Stroke Survivors.Journal of racial and ethnic health disparities · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mieke Van HemelrijckKing's College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, Research Oncology, Guy's Hospital, London, SE1 9RT, UK. mieke.vanhemelrijck@kcl.ac.uk
Monika Eichholzer
David Faeh
Sabine Rohrmann

Funding

Cancer Research UK
6 · The paper itself

Abstract

backgroundA score based on serum concentrations of C-reactive protein (CRP), albumin, gamma-glutamyl transferase (GGT), and HDL cholesterol was positively associated with death from cancer, circulatory disease, and all-cause mortality. We replicated this in the third National Health and Nutrition Examination Survey (NHANES III), a US nationally representative survey conducted between 1988-1994.

methodsBaseline measurements of CRP, albumin, GGT, and HDL were available for participants with mortality follow-up (n=13,056). A biomarker score, ranging 0-4, was created by adding number of markers with abnormal values (cut-off: CRP>10mg/L, albumin<35mg/L, GGT>36U/L, HDL<1.04mmol/L). Its association with mortality was analyzed with multivariate Cox proportional hazards models.

resultsThe score was positively associated with death from all causes, cancer and circulatory disease [e.g. HR all-cause mortality: 1.21 (95% CI: 1.09, 1.35), 1.92 (1.67, 2.20), 3.38 (2.62, 4.36), and 7.93 (5.77, 10.89), for score 1, 2, 3, 4 vs.0]. These patterns were found across the Charlson Comorbidity Index (CCI). Where CCI =3, risk of cancer death was 1.09 (0.93, 1.28), 1.81 (1.43, 2.29), 4.67 (3.05, 7.14), and 6.97 (5.32, 9.14) for score 1, 2, 3, 4 vs. 0. No effect-modification by sex or race/ethnicity was observed.

conclusionsThese findings correlate with results from a Swedish study. This biomarker-based score could help clinicians make decisions in prevention and disease management.

Indexed as

AdultAlbuminsBiomarkersCardiovascular DiseasesCause of DeathCholesterol, HDLC-Reactive ProteinCross-Sectional StudiesFemaleFollow-Up Studiesgamma-GlutamyltransferaseHumansMaleNeoplasmsNutrition SurveysPredictive Value of TestsAlbuminsBiomarkersCholesterol, HDLC-Reactive Proteingamma-Glutamyltransferase

Identifiers

PMID23092358
PMCPMC3549794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.